Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata referenced "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly report (Form 10-Q) for the three and nine months ended January 31, 2005.
Business Stage: Development stage company focused on perfluorocarbon-based medical products, primarily "Oxycyte" (a synthetic blood substitute), "Fluorovent" (lung treatment), and a glucose biosensor implant. The company has no revenue and relies on financing to fund clinical trials.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 2005 | Nine Months Ended Jan 31, 2005 | Balance Sheet (Jan 31, 2005) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(888,496) | $(1,961,877) | Accumulated Deficit: $(22,911,807) |
| Operating Expenses | $893,295 | $1,969,278 | N/A |
| Cash and Equivalents | N/A | N/A | $1,050,854 |
| Working Capital | N/A | N/A | $796,238 |
| Current Liabilities | N/A | N/A | $361,514 |
| Shares Outstanding | N/A | N/A | 125,534,918 |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the nine months ended Jan 31, 2005, increased to $1.96 million from $1.73 million in the prior year period. This was driven by a $226,714 increase in total expenses.
- Expense Drivers: General and Administrative (G&A) expenses rose significantly ($1.14M vs $0.74M prior year) due to a $311,000 non-cash expense for stock warrants granted for delayed stock registration and increased consulting fees. Research and Development (R&D) expenses decreased to $0.83M from $1.00M as the company focused resources on specific Phase II trial preparations.
- Liquidity Improvement: Cash and cash equivalents increased from $302,310 (April 30, 2004) to $1,050,854 (January 31, 2005), primarily due to $2.24 million in net cash provided by financing activities (sale of common stock).
Outlook, Risks, and Management Commentary
- Clinical Progress: Phase I trials for Oxycyte were completed in December 2003 with results meeting expectations. The company is actively enrolling patients for the first Phase II trial (hip surgery patients) and plans two additional Phase II trials in 2005 (coronary bypass/heart valve and surgical transfusion patients).
- Funding Needs: Management estimates the cost of pursuing Phase II trials in 2005 at $8,000,000. Current cash and recent funding are projected to sustain operations for approximately five months. The company is actively seeking private financing, strategic alliances, or joint ventures.
- Going Concern Risk: The filing explicitly states that the company's continuation as a going concern is dependent on obtaining additional financing. There is substantial doubt about the ability to continue operations without further capital.
- Accounting Changes: The company is currently using APB Opinion No. 25 for stock-based compensation but must adopt SFAS No. 123(R) effective August 1, 2005, which will require expensing share-based compensation using the fair value method, likely increasing reported losses.
Investor Verification Checklist
- Cash Runway: Verify if the company has secured the estimated $8 million needed for 2005 Phase II trials, given the current cash balance supports only ~5 months of operations.
- Subscription Agreement: Confirm the status of the $2.35 million subscription agreement from May 2004, which remains unpaid and is not currently relied upon for capital.
- Related Party Transactions: Review the $77,235 paid to a specialty contract manufacturer (where an officer is a minority shareholder) for Oxycyte production.
- Stock Dilution: Assess the impact of recent private placements (9.4 million shares issued in Dec 2004) and outstanding warrants on future share count and dilution.
- Regulatory Milestones: Monitor the enrollment and results of the Phase II clinical trials, as failure here would likely halt the primary revenue path.